Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is a radiopharmaceutical-focused company that produces and markets products used to Find, Fight and Follow cancer and diseases. The company has a strong portfolio of products that address unmet needs within the cardiology and oncology arenas, with leading products including PYLARIFY and DEFINITY. Despite potential competition and pressure on maintaining and expanding their commercial footprint, Lantheus is well-positioned for continued growth and success with its ongoing FDA approvals, anticipated pipeline growth, and strong financials. Additionally, the company has a strategic plan in place to secure reimbursement and maintain regulatory compliance, mitigating potential risks in those areas.

Bears say

Lantheus Holdings is performing well in the short term with strong revenue and margin beats in Q1. However, the focus on 2027 and lack of expected contributions from new opportunities dampen their long-term growth potential. While the royalty opportunities provide some upside, the stock is still undervalued and has room for growth, but not enough to justify a higher valuation in the near future.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.